Literature DB >> 30972661

The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events.

Evan Elias1, Laura E Targownik2.   

Abstract

A substantial volume of literature exists linking proton pump inhibitor (PPI) use with a multitude of serious adverse events. There is uncertainty, however, over whether these associations are clinically important. Excessive concern about PPI-related adverse events may leave patients at risk of harm by leaving acid-related upper gastrointestinal disease untreated. Conversely, the risk of treatments may outweigh the benefits if any of the purported adverse events are directly caused by PPI use; this is of particular concern where indications for PPI use are not present. In this paper, we review the studies which have reported associations between adverse events and PPI use, discuss the proposed mechanisms of action, grade the confidence in whether these associations are truly causal, and provide advice regarding balancing the benefits of PPI use against their possible harms.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30972661     DOI: 10.1007/s40265-019-01110-3

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  6 in total

1.  Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole.

Authors:  Wenjun Liu; Yong Xie; Yingmeng Li; Longjin Zheng; Qiuping Xiao; Xu Zhou; Qiong Li; Ni Yang; Kexuan Zuo; Tielong Xu; Nong-Hua Lu; Heping Zhang
Journal:  BMC Gastroenterol       Date:  2022-05-20       Impact factor: 2.847

2.  A Novel Risk Predictive Scoring Model for Predicting Subsequent Infection After Carbapenem-Resistant Gram-Negative Bacteria Colonization in Hematological Malignancy Patients.

Authors:  Qiuling Wu; Chenjing Qian; Hua Yin; Fang Liu; Yaohui Wu; Weiming Li; Linghui Xia; Ling Ma; Mei Hong
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

3.  Proton Pump Inhibitors Reduce Pancreatic Adenocarcinoma Progression by Selectively Targeting H+, K+-ATPases in Pancreatic Cancer and Stellate Cells.

Authors:  Marco Tozzi; Christiane E Sørensen; Lara Magni; Nynne M Christensen; Rayhana Bouazzi; Caroline M Buch; Matteo Stefanini; Claudia Duranti; Annarosa Arcangeli; Ivana Novak
Journal:  Cancers (Basel)       Date:  2020-03-10       Impact factor: 6.639

4.  The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model.

Authors:  Sarah Tomkovich; Nicholas A Lesniak; Yuan Li; Lucas Bishop; Madison J Fitzgerald; Patrick D Schloss
Journal:  mSphere       Date:  2019-11-20       Impact factor: 4.389

5.  Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system.

Authors:  Bin Wu; Dan Li; Ting Xu; Min Luo; Zhiyao He; Yuwen Li
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

6.  Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways.

Authors:  Ziping Cheng; Yangjie Liu; Mengyuan Ma; Shiyu Sun; Zengqing Ma; Yu Wang; Liyuan Yu; Xuping Qian; Luning Sun; Xuehui Zhang; Yun Liu; Yongqing Wang
Journal:  Mol Med       Date:  2022-02-19       Impact factor: 6.354

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.